The Art Of Histopathology

Discover the art of histopathology through the eyes of our most skilled scientists.

Immunohistochemistry biomarkers are key players in clinical development success. Tissue biomarkers can aid in the confirmation of diagnosis, patient selection, and/or for mechanistic evaluation.

Download our digital book to see the art of histopathology for yourself.

If you would like to know more about how Cerba Research can help you, our IHC expert scientific team will consult with you on your specific needs. Flexible in our approach and delivery to provide timely and cost effective solutions to meet your clinical and commercial objectives.

AACR 2022 poster. Using solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies

Our Histoprofile®- T-reg light panel is ready for use in your clinical trials

Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.

 

Amanda Finan

COVID-19 Therapy Development and Clinical Diagnostics

Analyzing Multiple Biomarkers with IHC: putting a 6-plex kit to the challenge

On November 16, 2021 Cerba Research and Akoya Biosciences held a webinar on how to analyze multiple biomarkers using Immunohistochemistry (IHC). The session was a deep dive in the Tissue Microenvironment (TME) with multiplex IF (Opal™) technology, discovering how to visualize, analyze, and quantify multiple phenotypes in situ.

As part of a long-standing collaboration with Akoya Biosciences, we agreed to test our pre-validated 6-plex panel kits, including one suitable for carcinoma immune-contexture investigations (CD8, CD68, FoxP3, PD1, PD-L1, PanCK). We were also able to put into practice Akoya’s pre-set imaging protocol on the Vectra® Polaris™ and related data analysis algorithm with inForm® software.

Speakers

  • Ivan Masetto, PhD, Field Application Scientist South of Europe at Akoya Biosciences
  • Maroua Tliba, Image Analyst at Cerba Research

The Value of Biomarkers from Discovery to Commercialization

Why do some patients respond to therapy while others do not? The answer can be found in the concept of biomarkers: objective, measurable indicators of the
presence or severity of disease. Used for decades to aid medical diagnosis, researchers today use biomarkers in every phase of drug discovery and development.
There’s good reason. Biomarkers can triple drug development success rates, accelerating the availability of new therapeutics.

Download our article by Jérôme Sallette, CSO at Cerba Research, to learn more on the advantages of biomarkers in clinical research.

CerbACT Asia – Center of Excellence in Immuno-Oncology

CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!

Download the flyer to learn more on CerbACT Asia’s capabilities.

Precision Medicine in Practice for Non-Small Cell Lung Cancer (NSCLC)

At the 16th Biomarkers UK Congress in November 2021, Rania Gaspo, PhD gave a talk on implementing precision medicine for Non-Small Cell Lung Cancer. How can you bring precision medicine into practice? What roles can Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and ctDNA play?

Webinar: Turning Precision Medicine into Action in Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.

Pediatric Phase I/II/III Study in X-Linked Myotubular Myopathy (XLMTM)

Lab support for a global pediatric trial for the rare neuromuscular disease, Myotubular Myopathy. Cerba Research provides safety testing, PBMC isolation, biomarkers, and sample management for the clinical trial. Read more on the challenges and solutions in the case study.

In Situ Multiplex Analysis of Regulatory and Effector T Cells in Multiple Tumor Types